• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症患者的全因住院情况。

All-cause hospitalizations in multiple sclerosis patients.

作者信息

Maia C, Costa A, Abreu P, Sa M J

机构信息

Hospital de Sao Joao, 4200-351 Porto, Portugal.

Universidade do Porto, Porto, Portugal.

出版信息

Rev Neurol. 2019 Mar 16;68(6):229-235. doi: 10.33588/rn.6806.2018281.

DOI:10.33588/rn.6806.2018281
PMID:30855706
Abstract

INTRODUCTION

There is poor knowledge on current hospitalizations in the multiple sclerosis (MS) population. The purpose of this study was to determine hospitalization causes and outcomes in a MS hospital-based cohort.

PATIENTS AND METHODS

A retrospective chart review was performed on all patients admitted at our centre between August, 2009 and July, 2015, excluding those with no previous established diagnosis.

RESULTS

308 hospitalizations were included, representing a total of 155 patients (female, 67.5%). Median age at hospitalizations was 47 years, with median disease duration of 12 years. The most common overall reason for hospitalization was infectious diseases (22.1%), followed by MS relapses (12.7%) and neurogenic bladder (11%). The median length of hospitalization for all patients was 5 days and the progressive subtype of MS had longer lengths of hospitalization than the relapsing-remitting MS. Intensive care unit admission occurred in 23 cases (7.5%) and were associated with increased mortality and length of hospitalization. Of the 308 hospitalizations, 9 (2.9%) resulted in death.

CONCLUSION

Infections are the most common cause of hospitalizations in our study, although MS relapses or complications related to MS continue to be significant causes of morbidity. Almost 8% of all MS hospitalizations required intensive care unit admission and these were related to longer admission lengths and higher death rates.

摘要

引言

对于目前多发性硬化症(MS)患者的住院情况了解不足。本研究的目的是确定以医院为基础的MS队列中的住院原因及结局。

患者与方法

对2009年8月至2015年7月期间在我们中心住院的所有患者进行回顾性病历审查,排除既往未确诊的患者。

结果

纳入308次住院病例,共155例患者(女性占67.5%)。住院时的中位年龄为47岁,疾病中位病程为12年。住院最常见的总体原因是感染性疾病(22.1%),其次是MS复发(12.7%)和神经源性膀胱(11%)。所有患者的中位住院时间为5天,MS的进展型亚型的住院时间比复发缓解型MS更长。23例(7.5%)患者入住重症监护病房,且与死亡率增加和住院时间延长相关。在308次住院病例中,9例(2.9%)导致死亡。

结论

在我们的研究中,感染是住院最常见的原因,尽管MS复发或与MS相关的并发症仍然是发病的重要原因。几乎8%的MS住院患者需要入住重症监护病房,且这些与更长的住院时间和更高的死亡率相关。

相似文献

1
All-cause hospitalizations in multiple sclerosis patients.多发性硬化症患者的全因住院情况。
Rev Neurol. 2019 Mar 16;68(6):229-235. doi: 10.33588/rn.6806.2018281.
2
Impact of comorbidity on hospitalizations in individuals newly diagnosed with multiple sclerosis: A longitudinal population-based study.新诊断多发性硬化症患者合并症对住院的影响:一项基于人群的纵向研究。
Mult Scler Relat Disord. 2020 May;40:101955. doi: 10.1016/j.msard.2020.101955. Epub 2020 Jan 22.
3
Predictors of hospitalization in a Canadian MS population: A matched cohort study.加拿大多发性硬化症人群住院的预测因素:一项匹配队列研究。
Mult Scler Relat Disord. 2020 Jun;41:102028. doi: 10.1016/j.msard.2020.102028. Epub 2020 Feb 27.
4
Hospital admissions and MS: temporal trends and patient characteristics.住院治疗与多发性硬化症:时间趋势和患者特征。
Am J Manag Care. 2012 Nov;18(11):735-42.
5
Thirty-day readmissions in multiple sclerosis: An age and gender-based US national retrospective analysis.多发性硬化症 30 天再入院率:基于年龄和性别的美国全国回顾性分析。
Mult Scler Relat Disord. 2019 Jun;31:41-50. doi: 10.1016/j.msard.2019.03.012. Epub 2019 Mar 20.
6
All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre.来自加拿大大型转诊中心的系统性红斑狼疮全因住院治疗。
Rheumatology (Oxford). 2013 May;52(5):905-9. doi: 10.1093/rheumatology/kes391. Epub 2013 Jan 9.
7
Dramatically changing rates and reasons for hospitalization in multiple sclerosis.多发性硬化症住院率和住院原因的急剧变化。
Neurology. 2014 Sep 2;83(10):929-37. doi: 10.1212/WNL.0000000000000753. Epub 2014 Aug 1.
8
Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.对多发性硬化症疾病修正疗法的依从性及后续住院情况。
Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):702-711. doi: 10.1002/pds.4207. Epub 2017 Apr 3.
9
Comorbidity increases the risk of hospitalizations in multiple sclerosis.合并症会增加多发性硬化症患者住院的风险。
Neurology. 2015 Jan 27;84(4):350-8. doi: 10.1212/WNL.0000000000001187. Epub 2014 Dec 24.
10
Health care utilization before and after intensive care unit admission in multiple sclerosis.重症监护病房收治前后多发性硬化症患者的医疗服务利用情况
Mult Scler Relat Disord. 2015 Jul;4(4):296-303. doi: 10.1016/j.msard.2015.05.010. Epub 2015 May 30.

引用本文的文献

1
Reasons for Hospital Admission in Individuals With Multiple Sclerosis.多发性硬化症患者的住院原因。
Int J MS Care. 2024 Oct 28;26(Q4):302-307. doi: 10.7224/1537-2073.2023-064. eCollection 2024 Oct.
2
Impact of COVID-19 and system recovery in delivering healthcare to people with multiple sclerosis: a population-based Study.COVID-19 对多发性硬化症患者医疗服务的影响和系统恢复:基于人群的研究。
Neurol Sci. 2023 Nov;44(11):3771-3779. doi: 10.1007/s10072-023-07052-9. Epub 2023 Sep 6.
3
The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer's perspective.
阿仑单抗在厄瓜多尔基多市多发性硬化症治疗中的预算影响。支付方视角。
Glob Reg Health Technol Assess. 2021 Oct 21;8:140-146. doi: 10.33393/grhta.2021.2273. eCollection 2021 Jan-Dec.
4
Risk and outcomes of COVID-19 in patients with multiple sclerosis.COVID-19 风险和多发性硬化症患者的结局。
Eur J Neurol. 2021 Nov;28(11):3712-3721. doi: 10.1111/ene.14990. Epub 2021 Jul 18.
5
Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources.富马酸二甲酯在真实世界临床实践中的有效性以及将不良反应和医疗资源使用降至最低的策略。
Patient Prefer Adherence. 2021 Jan 29;15:149-158. doi: 10.2147/PPA.S284425. eCollection 2021.
6
Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.巴西公共医疗体系中,用于 RRMS 二线治疗的那他珠单抗与芬戈莫德的年化住院率:基于索赔数据库的研究方法。
PLoS One. 2020 Mar 2;15(3):e0229768. doi: 10.1371/journal.pone.0229768. eCollection 2020.